Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Phase 3 Lupus Nephritis Trials

4 Phase 3 trials for Lupus Nephritis. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT04702256

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus...

This is a randomised, open label, controlled non-inferiority phase III multicentre trial. As primary objective, the study aims to demonstrate that a regimen free of additional...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1961 location
RECRUITINGPhase 3NCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With...

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination...

Sponsor: Novartis PharmaceuticalsEnrolling: 46220 locations
RECRUITINGPhase 3NCT06904729

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus...

Sponsor: Guangzhou Women and Children's Medical CenterEnrolling: 501 location
RECRUITINGPhase 3NCT06406205

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.

Sponsor: Qilu Pharmaceutical Co., Ltd.Enrolling: 27010 locations